A clinical study to evaluate the efficacy of degarelix in prostate cancer patients
Phase of Trial: Phase IV
Latest Information Update: 19 Feb 2019
Price : $35 *
At a glance
- Drugs Degarelix (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 15 Feb 2019 Status changed from recruiting to discontinued.
- 29 Jun 2017 Status changed from not yet recruiting to recruiting.
- 17 Sep 2014 New trial record